Zydus Lifesciences Ltd (BOM:532321) reports a robust 17% revenue increase and significant advancements in its innovation pipeline amidst market challenges.

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which ...

Zydus Lifesciences Limited reports 30% profit increase, driven by US formulations business, with strong financial position ...

The United States is the company's biggest market accounting for 47 per cent of total revenue, followed by India ...

Zydus Lifesciences on Wednesday said consolidated net profit increased by 30 per cent to Rs 1,023 crore for the third quarter ended December 31, 2024, aided by robust sales across domestic and US ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.